Clinical trial
A Trial of the ALK Grass Tablet in Subjects With Hayfever
NCT00227279 · ALK-Abelló A/S, Industry · Completed
Key facts
| NCT number | NCT00227279 |
|---|---|
| Title | A Trial of the ALK Grass Tablet in Subjects With Hayfever |
| Official title | A Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis |
| Lead sponsor | ALK-Abelló A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Biological |
| Interventions | ALK Grass tablet |
| Enrollment | 634 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Sep 28, 2005 |
| Last update posted | Jan 29, 2013 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: